Marek Wardęcki

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Hannele Yki‐Järvinen, Richard M. Bergenstal, M. Ziemen et al. · Diabetes Care · 2014 · 274 citations

Metabolic Syndrome, Diabetes Management, Basal Insulin +15

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

H Yki-Järvinen, Richard M. Bergenstal, Geremia B. Bolli et al. · Diabetes Obesity and Metabolism · 2015 · 131 citations · Full text

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

Julio Rosenstock, Bruno Guerci, M Hanefeld et al. · Diabetes Care · 2016 · 129 citations · Full text

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini et al. · Blood · 2022 · 103 citations · Full text

Immunohematology, Cadenza Trial, Immunodeficiencies +17

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

Matthew C. Riddle, Geremia B. Bolli, Philip Home et al. · Diabetes Technology & Therapeutics · 2016 · 48 citations · Full text